Jennifer Jarrett's departure as Chief Operating Officer of Arcus Biosciences, Inc. was reported, effective March 30, 2026; the filing names no successor. As of November 14, 2026, Arcus Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 23, 2026, naming 1 departure (Form 8-K, March 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Arcus Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Arcus Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Arcus Biosciences, Inc. files it.
Also on the record for Arcus Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13D/A, by Gilead Sciences, Inc. | 24.7% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 10.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 4.1% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13D/A, by GILEAD SCIENCES, INC. | 25.6% of the class | 5%+ stakes | Source |
| July 15, 2025 | Stake report, Schedule 13D/A, by GILEAD SCIENCES, INC. | 29.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Arcus Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Arcus Biosciences, Inc. and the records around it.
Arcus Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026), Arcellx, Inc. (Apr 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Arcus Biosciences, Inc.
Get an email when Arcus Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcus Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arcus Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcus Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-23 | Out | Chief Operating Officer | 2026-03-30 | 8-K, 2026-03-23 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Jennifer Jarrett, Chief Operating Officer (filed 2026-03-23):
Ms. Jarrett's resignation is not the result of any disagreement with the Company regarding its operations, policies or practices.
Who leads Arcus Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Jennifer Jarrett, departure reported, effective 2026-03-30 (filed 2026-03-23). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Arcus Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Arcus Biosciences, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Arcus Biosciences, Inc.Every change, in the filing's words
Departing: Jennifer Jarrett, Chief Operating Officer, effective 2026-03-30
On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the "Company") of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026.
- The Company and Ms. Jarrett entered into a separation agreement pursuant to which Ms. Jarrett will make herself available for periodic advisory services for a period through June 30, 2026.
- In consideration for such services, the Company agreed to extend the post-termination option exercise period during which she may continue to exercise any vested options to twelve (12) months.
- The separation agreement also contains a standard release of claims.
Tools for this story
Each opens in a new tab, filled in for Arcus Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
